Patients with insulin resistance and steatosis show signs of reduced microbial gene richness and increased genetic potential for processing of dietary lipids and endotoxin biosynthesis (notably from Proteobacteria), hepatic inflammation and dysregulation of aromatic and branched-chain amino acid (AAA and BCAA) metabolism [10] .
In subjects with NAFLD disease progression to advanced fibrosis is characterized by statistically significant increase in abundance of the Proteobacteria phylum a while the Firmicutes phylum decreases [11] .
Analysis of microbiota communities in human oral, gut, and atherosclerotic plaques from individuals with established atherosclerosis showed a reproducible correlation between CVD and bacterial pathogens, including Chlamydia pneumoniae, Porphyromonas gingivalis, Helicobacter pylori, and Aggregatibacter actinomycetemcomitans [12] . Another study found that Collinsella spp. are enriched in subjects with atherosclerosis, while Eubacterium spp. and Roseburia spp. are more abundant among healthy controls [13] . Finally, research over the past decade has uncovered several key microbial metabolites, such as trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs) and secondary bile acids that uniquely affect the progression of CVD [5] .
Few contributions about microbiota were published in Acta Diabetologica in the last 5 years [14] [15] [16] [17] [18] . However, given its relevance, we open a new topical collection dedicated to the gut microbiome and its impact on metabolic disorders. Dumas and colleagues discussed the relevance of Diet-Induced Metabolic Changes of the Human Gut Microbiome and in particular they focus on microbie-derived metabolites such as short-chain fatty acids, methylamines and indoles [19] . Fernandez Real and colleagues showed new evidence connecting glutamate to gut microbiota composition and metabolic phenotypes [20] . Finally, Liang Ma and colleagues illustrated the links between gut microbiota and diabetic nephropathy [21] . 
